EMPA-REG OUTCOME - a long-term, outcom study of empagliflozin in pateints with T2D at high CV risk

Principal investigator presenting the results of EMPA-REG OUTCOME trial

Landmark EMPA-REG OUTCOME trial demonstrates superiority in T2D at risk for CV events

New dual therapeutic approach basal insulin and GLP1-analogue in the ADA/EASD Position Statement: theory, evidence and clinical implications

The importance of hypoglycemia in the treatment of diabetes mellitus

How to decrease hypoglycemia episodes of diabetic patients in the daily practice?

Update 2015 on the DPP4 inhibitors

Novelties in the incretin therapy at EASD 2015: combination with basal insulin and SGLT2 inhibitors, the pleiotropic effect

Breakthrough results in diabetes treatment: the EMPA-REG OUTCOME trial

Highlights of EASD 2015 Congress

Importance of weight management in diabetes mellitus

Role of DDP4 inhibitors in the treatment of T2DM

Advancement and challenges in the treatment of diabetes mellitus

GLP1 analogues in weight management: mechanism of action

Cardiovascular protection in T2DM with focus on the EMPA-REG trial results

Protecting the kidney in diabetes: therapeutic opportunities and challenges

Hot topics of the EASD 2015 Congress

Weight control with liraglutide 3.0 mg: the SCALE trial program